Medicare Diabetic Foot Ulcer Care Improvement and Savings Act of 1999 - Amends title XVIII (Medicare) of the Social Security Act to provide for Medicare coverage of certain biologicals used in treating lower extremity ulcers in patients with diabetes.
[Congressional Bills 106th Congress]
[From the U.S. Government Publishing Office]
[H.R. 2369 Introduced in House (IH)]
106th CONGRESS
1st Session
H. R. 2369
To amend title XVIII of the Social Security Act to provide for Medicare
coverage of certain biologicals used in treating lower extremity ulcers
in patients with diabetes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
June 29, 1999
Mr. Nethercutt (for himself and Mr. LaFalce) introduced the following
bill; which was referred to the Committee on Commerce, and in addition
to the Committee on Ways and Means, for a period to be subsequently
determined by the Speaker, in each case for consideration of such
provisions as fall within the jurisdiction of the committee concerned
_______________________________________________________________________
A BILL
To amend title XVIII of the Social Security Act to provide for Medicare
coverage of certain biologicals used in treating lower extremity ulcers
in patients with diabetes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Medicare Diabetic Foot Ulcer Care
Improvement and Savings Act of 1999''.
SEC. 2. MEDICARE COVERAGE OF CERTAIN BIOLOGICALS USED IN TREATING LOWER
EXTREMITY ULCERS IN PATIENTS WITH DIABETES.
(a) In General.--Section 1861(s)(2) of the Social Security Act (42
U.S.C. 1395x(s)(2)) is amended--
(1) by striking ``and'' at the end of subparagraph (S);
(2) by striking the period at the end of subparagraph (T)
and inserting ``; and''; and
(3) by inserting after subparagraph (T) the following new
subparagraph:
``(U) recombinant human growth factor (which is
approved by the Food and Drug Administration)
prescribed for use in the treatment of a lower
extremity neuropathic ulcer in an individual with
diabetes;''.
(b) Effective Date.--The amendments made by subsection (a) apply to
items furnished on or after October 1, 1999.
<all>
Introduced in House
Introduced in House
Sponsor introductory remarks on measure. (CR E1440)
Referred to the Committee on Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Referred to the Subcommittee on Health and Environment.
Llama 3.2 · runs locally in your browser
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line